𝔖 Bobbio Scriptorium

✦ LIBER ✦

The Role of External Beam Radiotherapy with or without Concurrent Chemotherapy in the Treatment for Unresectable Locally Advanced Hilar Cholangiocarcinoma

✍ Scribed by P. Huang; Y. Chen; Y. Hu; C. Shiau; Y. Liu; L. Wang; Y. Chao; S. Yen

Book ID: 118456161
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 41 KB
Volume: 81
Category: Article
ISSN: 0360-3016
DOI: 10.1016/j.ijrobp.2011.06.1841

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hyperfractionated radiotherapy (Hfx RT)

Hyperfractionated radiotherapy (Hfx RT) with or without concurrent low-dose daily cisplatin (CDDP) in locally advanced unresectable squamous cell carcinoma of the head and neck (SCC H&N). A prospective randomized trial

✍ B. Jeremic; Y. Shibamoto; B. Milicic; N. Nikolic; A. Dagovic 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 186 KB

A Phase I Study of Bortezomib in Combina

A Phase I Study of Bortezomib in Combination With Standard 5-Fluorouracil and External-Beam Radiation Therapy for the Treatment of Locally Advanced or Metastatic Rectal Cancer

✍ Bert H. O'Neil; Laura Raftery; Benjamin F. Calvo; A. Bapsi Chakravarthy; Anastas 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 477 KB

825 Poster Standard fraction (CF) or hyp

825 Poster Standard fraction (CF) or hyperfractionated radiotherapy (Hfx RT) with or without concurrent low-dose daily platinum chemotherapy (CHT) in patients with locally advanced non-metastatic squamous cell carcinoma of the head and neck (SCC H&N). Almost perfect retrospective trial

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 159 KB

1015 Abnormal P-53 suppressor gene expre

1015 Abnormal P-53 suppressor gene expression predicts for a poorer outcome in patients with locally advanced adenocarcinoma of the prostate treated by external beam radiation therapy with or without pre-radiation androgen ablation: Results based on RTOG study 86-10

✍ Colleen A. Lawton; David Grignon; Richard Caplan; Fazlul Sarkar; Jeffrey Forman; 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 88 KB

8LBA Biomarker evaluation in the randomi

8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

✍ B. Johnson; V. Miller; L. Amler; H. Stern; C. Soh; P. O'Connor; F. Kabbinavar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB